Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
Retrieved on:
Tuesday, September 28, 2021
Retina, Optic nerve, Johns Hopkins School of Medicine, Trial of the century, Annual report, Compliance, Observation, Extension, Security (finance), CST, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, AMD, Patient, Core, MD, Form 10-K, Doctor of Pharmacy, Visual acuity, Disease management, Sunitinib, Risk, VEGF, COVID-19, Technology, Forward-looking statement, Safety, Glaucoma, Doctor of Philosophy, GLOBE, Pharmaceutical industry, Sintering
The second phase of ALTISSIMO was a six-month extended observation phase, or Extension Study, in which patients were monitored without additional treatment to determine the duration of effect measured from their last treatment during the Core Study.
Key Points:
- The second phase of ALTISSIMO was a six-month extended observation phase, or Extension Study, in which patients were monitored without additional treatment to determine the duration of effect measured from their last treatment during the Core Study.
- Participation in the Extension Study was voluntary, but only patients who completed all study visits, and did not require supportive therapy at their Month 12 visit during the Core Study, were eligible.
- This is the longest duration ever achieved with an intravitreal injection in a randomized, masked, and controlled clinical trial in wet AMD.
- As in the Core Study, GB-102 1mg continued to be well-tolerated and maintained a favorable safety profile during the Extension Study.